Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of dmLT ETEC Vaccine
NCT02531685Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jun 2016
- Primary completion
- May 2020
- Modality
- Recombinant Proteins and Enzymes, Liposomes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of dmLT in enterotoxigenic Escherichia coli infection (5 cohorts), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Occurrence of solicited adverse events and Occurrence of vaccine-related, non-solicited adverse events. Started Jun 2016; status: completed.
02
Drugs
dmLT
03
Conditions
enterotoxigenic Escherichia coli infection
Beyond the preview
Go deeper on NCT02531685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02531685.